Related references
Note: Only part of the references are listed.MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
Scott J. Rodig et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Daniel Sanghoon Shin et al.
CANCER DISCOVERY (2017)
Whole-genome landscapes of major melanoma subtypes
Nicholas K. Hayward et al.
NATURE (2017)
Identification of essential genes for cancer immunotherapy
Shashank J. Patel et al.
NATURE (2017)
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Robert T. Manguso et al.
NATURE (2017)
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
Whijae Roh et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Tumor-associated B-cells induce tumor heterogeneity and therapy resistance
Rajasekharan Somasundaram et al.
NATURE COMMUNICATIONS (2017)
Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions
Antje Sucker et al.
NATURE COMMUNICATIONS (2017)
Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma A Systematic Review and Network Meta-analysis of Randomized Clinical Trials
Tahira Devji et al.
JAMA ONCOLOGY (2017)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas et al.
CELL (2017)
Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening
E. Robert McDonald et al.
CELL (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
Jianjun Gao et al.
CELL (2016)
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Joseph L. Benci et al.
CELL (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
Jonathan M. Pitt et al.
IMMUNITY (2016)
LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors
Ying Cheng et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Landscape of tumor-infiltrating T cell repertoire of human cancers
Bo Li et al.
NATURE GENETICS (2016)
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The molecular profile of metastatic melanoma in Australia
Megan Lyle et al.
PATHOLOGY (2016)
Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells
Shu Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
Paul E. Hughes et al.
TRENDS IN IMMUNOLOGY (2016)
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Vinit Kumar et al.
TRENDS IN IMMUNOLOGY (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama et al.
NATURE COMMUNICATIONS (2016)
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
Douglas B. Johnson et al.
NATURE COMMUNICATIONS (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Sebastian Kreiter et al.
NATURE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
SETDB1 accelerates tumourigenesis by regulating the WNT signalling pathway
Qiao-Yang Sun et al.
JOURNAL OF PATHOLOGY (2015)
LNK (SH2B3): paradoxical effects in ovarian cancer
L-W Ding et al.
ONCOGENE (2015)
Genome-Wide Association Study Identifies Variants Associated With Autoimmune Hepatitis Type 1
Ynto S. de Boer et al.
GASTROENTEROLOGY (2014)
Genetic loss of SH2B3 in acute lymphoblastic leukemia
Arianne Perez-Garcia et al.
BLOOD (2013)
Melanoma Epidemic: An Analysis of Six Decades of Data From the Connecticut Tumor Registry
Alan C. Geller et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Michael S. Lawrence et al.
NATURE (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Role of the adaptor protein LNK in normal and malignant hematopoiesis
S. Gery et al.
ONCOGENE (2013)
DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications
Hsin-An Hou et al.
BLOOD (2012)
14-3-3 regulates the LNK/JAK2 pathway in mouse hematopoietic stem and progenitor cells
Jing Jiang et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
IFN-α in the Treatment of Melanoma
Ahmad A. Tarhini et al.
JOURNAL OF IMMUNOLOGY (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The adaptor Lnk (SH2B3): An emerging regulator in vascular cells and a link between immune and inflammatory signaling
Julie Devalliere et al.
BIOCHEMICAL PHARMACOLOGY (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Lnk constrains myeloproliferative diseases in mice
Alexey Bersenev et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations
A. Pardanani et al.
LEUKEMIA (2010)
LNK Mutations in JAK2 Mutation-Negative Erythrocytosis.
Terra L. Lasho et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F
Sigal Gery et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2009)
Newly identified genetic risk variants for celiac disease related to the immune response
Karen A. Hunt et al.
NATURE GENETICS (2008)
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
AV Jones et al.
BLOOD (2005)
Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways
W Tong et al.
BLOOD (2005)
Mechanisms of Interferon-alpha induced apoptosis in malignant cells
L Thyrell et al.
ONCOGENE (2002)
Share Paper
